There is an increasing incidence of GI cancers as per the Cancer Registry Data. In such a situation, it is essential to evaluate the patient by standard investigational tools like clinical examination and endoscopy which help in establishing the diagnosis. Determination of tumour markers is useful not only in diagnosis and prognosis of cancer but also monitoring of cancer treatment. Tumour markers in GI oncology include oncofoetal proteins, hormones, enzymes and cancer antigens. Recent advances include application of tumour marker level determination combined with newer radiological and functional imaging such as FDG PET -CT.
Introduction
Tumour markers are substances that can be detected in higher-than-normal amounts in the blood, urine, or body tissues of some patients with certain types of cancer. Most tumour markers can be elevated in patients who do not have a tumour; and, no tumour marker is entirely specifi c to a particular type of cancer. The carcinoembryonic antigen (CEA) is one of the fi rst Tumour markers identifi ed in making the diagnosis of colorectal cancer.
Gastrointestinal (GI) malignancies including pancreatic cancers have begun to rise in Asia. There is an alarming rise in the incidence of GI malignancies in our country. According to the PBCR, incidence of colorectal cancer in males is 2.92 and 2.30 [1] in females in Bangalore. The common question posed to the surgeon is -is there a marker in tissue or serum which detects the presence of malignancy without being an invasive procedure? Whether absence of the marker post-treatment ensures "cure"?
Tumour markers
These are cellular products that are abnormally detected in malignancies [2] . These markers can be detected in various body fl uids and on the surface of cancer cells. The perfect tumour marker would be one that is -1. Produced only by the tumour cell. 2. Present in all patients with the said cancer. 3. Levels in the blood correlating with the tumour burden. 4. Detectable in occult disease. 5. Absent in benign disease. There is no tumour marker which meets the above requirements. The utility of tumour markers depends on its sensitivity, specifi city and variability in assays. The measurements that help defi ne the utility of the tumour markers are: Determination of these tumour markers can be used in:
1. Diagnosis 2. Prognosis of the cancer 3. Monitoring of treatment
Classifi cation of tumour markers
The markers can be classifi ed in several ways: According to their chemical structure, tissue of origin, site of malignancies and functionality. The most common classifi cation is depicted in Table 1 . 
Usefulness of tumour markers in GI malignancies (site specifi c)

Ooesophageal cancer
Neoangiogenesis and lymph angiogenesis represent prognostic factor in human malignancies. Determination of microvessel density [4] (MVD) by immunohistology has been investigated by CD-31 staining and quantifi cation in tumour samples of patients with ooesophageal cancer for real time PCR analyses of VEGFR-2, VEGFR-3. It has been found that MVD was signifi cantly linked to the expression of VEGF-A, C, D and Ang 1 and Ang 2 and this represents a novel tool to study the association of ooesophageal carcinoma with lymph node metastasis.
Gastric cancer
CEA level is elevated in approximately one third of patients with primary gastric cancer [5] . The sensitivity of CEA as a tumour marker of gastric cancer is low [6] however if CEA level is elevated it usually correlates with stage of the disease. Combining CEA with other tumour markers like can increase sensitivity to CEA alone [6, 7, 8] . CEA was increased in 42.5% of gastric cancer in Indian publication [9] .
Gastrointestinal stromal tumours (GIST)
These are histologically heterogeneous group of mesenchymal tumours arising from the GIT (spindle or epitheloid neoplasm). The hallmark of this condition is the expression 
